Free Trial
→ Refund From 1933: Trump’s Reset May Create Instant Wealth (From American Hartford Gold) (Ad)tc pixel Free MXCT Stock Alerts

MaxCyte (MXCT) Financials

MaxCyte logo
$1.64 +0.02 (+0.93%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for MaxCyte

Annual Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -24 -38 -41
Consolidated Net Income / (Loss)		 -24 -38 -41
Net Income / (Loss) Continuing Operations		 -24 -38 -41
Total Pre-Tax Income 		-24 -38 -41
Total Operating Income		 -27 -48 -51
Total Gross Profit		 39 37 32
Total Revenue		 44 41 39
Operating Revenue		 44 41 39
Total Cost of Revenue		 5.10 4.74 7.10
Operating Cost of Revenue		 5.10 4.74 7.10
Total Operating Expenses		 67 85 83
Selling, General & Admin Expense		 26 30 30
Marketing Expense		 19 27 27
Research & Development Expense		 20 24 22
Depreciation Expense		 2.53 3.99 4.14
Total Other Income / (Expense), net		 3.79 10 10
Interest & Investment Income		 3.92 10 10
Income Tax Expense		 0.00 0.00 0.00
Basic Earnings per Share		 ($0.23) ($0.37) ($0.39)
Weighted Average Basic Shares Outstanding		 101.70M 103.27M 104.85M
Diluted Earnings per Share		 ($0.23) ($0.37) ($0.39)
Weighted Average Diluted Shares Outstanding		 101.70M 103.27M 104.85M
Weighted Average Basic & Diluted Shares Outstanding		 102.90M 104.13M 106.03M

Quarterly Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Consolidated Net Income / (Loss)		 -6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Net Income / (Loss) Continuing Operations		 -6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Total Pre-Tax Income 		-6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Total Operating Income		 -7.71 -6.75 -13 -13 -14 -8.10 -12 -12 -14 -13
Total Gross Profit		 9.27 11 7.58 7.67 7.21 14 9.94 8.94 6.24 6.41
Total Revenue		 11 12 8.58 9.04 8.00 16 11 10 8.16 8.69
Operating Revenue		 11 12 8.58 9.04 8.00 16 11 10 8.16 8.69
Total Cost of Revenue		 1.37 1.55 1.00 1.38 0.79 1.57 1.40 1.49 1.93 2.28
Operating Cost of Revenue		 1.37 1.55 1.00 1.38 0.79 1.57 1.40 1.49 1.93 2.28
Total Operating Expenses		 17 18 21 21 21 22 22 21 20 19
Selling, General & Admin Expense		 6.44 5.65 7.50 7.66 6.82 8.09 7.10 7.64 7.75 7.21
Marketing Expense		 4.51 5.38 6.30 6.44 7.05 7.20 7.37 6.62 6.21 6.47
Research & Development Expense		 5.33 5.73 6.05 5.66 6.26 5.84 6.68 5.62 5.32 4.61
Depreciation Expense		 0.71 0.87 0.91 0.98 1.03 1.06 1.07 1.03 1.02 1.02
Total Other Income / (Expense), net		 1.28 1.94 2.30 2.56 2.70 2.82 2.75 2.59 2.50 2.30
Interest & Investment Income		 1.39 1.95 2.30 2.56 2.70 2.82 2.75 2.59 2.50 2.30
Basic Earnings per Share		 ($0.06) ($0.05) ($0.11) ($0.10) ($0.11) ($0.05) ($0.09) ($0.09) ($0.11) ($0.10)
Weighted Average Basic Shares Outstanding		 101.81M 101.70M 102.85M 103.06M 103.45M 103.27M 104.09M 104.64M 105.11M 104.85M
Weighted Average Diluted Shares Outstanding		 101.81M 101.70M 103.05M 103.06M 103.45M 103.27M 104.54M 104.64M 105.11M 104.85M
Weighted Average Basic & Diluted Shares Outstanding		 102.05M 102.90M 103.05M 103.50M 103.58M 104.13M 104.54M 105.09M 105.48M 106.03M

Annual Cash Flow Statements for MaxCyte

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -37 35 -19
Net Cash From Operating Activities		 -15 -22 -28
Net Cash From Continuing Operating Activities		 -15 -22 -28
Net Income / (Loss) Continuing Operations		 -24 -38 -41
Consolidated Net Income / (Loss)		 -24 -38 -41
Depreciation Expense		 2.70 4.17 4.32
Amortization Expense		 -2.67 -6.73 -5.77
Non-Cash Adjustments To Reconcile Net Income		 11 17 16
Changes in Operating Assets and Liabilities, net		 -2.07 1.91 -0.75
Net Cash From Investing Activities		 -25 55 6.93
Net Cash From Continuing Investing Activities		 -25 55 6.93
Purchase of Property, Plant & Equipment		 -18 -3.70 -1.65
Purchase of Investments		 -291 -255 -151
Sale of Property, Plant & Equipment		 0.00 0.01 0.00
Sale and/or Maturity of Investments		 285 314 159
Net Cash From Financing Activities		 2.89 2.14 2.06
Net Cash From Continuing Financing Activities		 2.89 2.14 2.06
Issuance of Common Equity		 0.00 0.27 0.46
Other Financing Activities, net		 2.89 1.87 1.60

Quarterly Cash Flow Statements for MaxCyte

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -66 -32 27 17 -5.39 -2.67 -24 15 -0.56 -9.07
Net Cash From Operating Activities		 -5.92 -6.09 -4.32 -10 -8.24 0.98 -11 -4.83 -4.39 -7.82
Net Cash From Continuing Operating Activities		 -5.92 -6.09 -4.32 -10 -8.24 0.98 -11 -4.83 -4.39 -7.82
Net Income / (Loss) Continuing Operations		 -6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Consolidated Net Income / (Loss)		 -6.43 -4.81 -11 -11 -11 -5.28 -9.53 -9.38 -12 -11
Depreciation Expense		 0.74 0.92 0.96 1.03 1.08 1.10 1.11 1.08 1.07 1.06
Amortization Expense		 -0.95 -1.51 -1.73 -1.91 -1.48 -1.60 -1.98 -1.68 -1.39 -0.72
Non-Cash Adjustments To Reconcile Net Income		 3.82 6.26 4.46 4.84 1.69 5.89 3.17 3.82 4.52 4.15
Changes in Operating Assets and Liabilities, net		 -3.09 -6.95 2.86 -3.55 1.73 0.87 -3.34 1.33 2.97 -1.71
Net Cash From Investing Activities		 -61 -27 30 27 2.81 -4.14 -14 19 3.61 -1.67
Net Cash From Continuing Investing Activities		 -61 -27 30 27 2.81 -4.14 -14 19 3.61 -1.67
Purchase of Property, Plant & Equipment		 -3.48 -2.19 -1.56 -0.51 -0.72 -0.92 -0.80 -0.29 -0.41 -0.15
Purchase of Investments		 -82 -77 -58 -47 -81 -69 -48 -31 -39 -33
Sale and/or Maturity of Investments		 25 53 89 74 84 66 34 51 43 31
Net Cash From Financing Activities		 0.44 1.23 1.46 0.16 0.04 0.49 0.70 0.71 0.23 0.41
Net Cash From Continuing Financing Activities		 0.44 1.23 1.46 0.16 0.04 0.49 0.70 0.71 0.23 0.41
Issuance of Common Equity		 - - 0.00 - - 0.27 0.00 0.27 - 0.19
Other Financing Activities, net		 0.44 1.23 1.46 0.16 0.04 0.22 0.70 0.45 0.23 0.22

Annual Balance Sheets for MaxCyte

This table presents MaxCyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 287 268 239
Total Current Assets		 252 190 172
Cash & Equivalents		 11 47 28
Short-Term Investments		 216 122 127
Accounts Receivable		 13 5.78 4.68
Inventories, net		 8.58 12 8.91
Prepaid Expenses		 3.26 3.90 3.61
Plant, Property, & Equipment, net		 24 24 20
Total Noncurrent Assets		 11 55 48
Long-Term Investments		 0.00 43 36
Other Noncurrent Operating Assets		 11 12 12
Total Liabilities & Shareholders' Equity		 287 268 239
Total Liabilities		 33 36 33
Total Current Liabilities		 15 18 16
Accounts Payable		 0.29 0.74 1.36
Accrued Expenses		 8.27 11 8.30
Current Deferred Revenue		 6.71 5.07 5.25
Other Current Liabilities		 0.16 0.77 0.86
Total Noncurrent Liabilities		 17 18 17
Other Noncurrent Operating Liabilities		 17 18 17
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 254 232 206
Total Preferred & Common Equity		 254 232 206
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 254 232 206
Common Stock		 392 408 423
Retained Earnings		 -138 -176 -217

Quarterly Balance Sheets for MaxCyte

This table presents MaxCyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 286 282 271 267 258 251 249
Total Current Assets		 252 246 237 214 179 176 173
Cash & Equivalents		 43 38 55 49 22 38 37
Short-Term Investments		 190 187 162 141 135 120 117
Accounts Receivable		 8.21 9.29 7.61 8.17 5.99 4.58 4.56
Inventories, net		 7.91 10 11 13 12 11 10
Prepaid Expenses		 3.28 2.23 1.88 3.40 3.21 2.58 4.12
Plant, Property, & Equipment, net		 23 25 24 24 23 22 21
Total Noncurrent Assets		 11 10 10 29 56 54 55
Long-Term Investments		 - - - 18 45 42 43
Other Noncurrent Operating Assets		 11 10 10 10 11 12 12
Total Liabilities & Shareholders' Equity		 286 282 271 267 258 251 249
Total Liabilities		 32 34 30 33 32 30 35
Total Current Liabilities		 17 17 13 17 13 12 18
Accounts Payable		 2.09 3.50 1.60 0.45 1.67 0.95 1.87
Accrued Expenses		 8.23 6.91 6.41 9.92 6.50 7.08 8.20
Current Deferred Revenue		 6.29 5.75 4.69 5.59 4.48 3.37 6.65
Other Current Liabilities		 0.15 0.48 0.50 0.70 0.83 0.88 0.91
Total Noncurrent Liabilities		 15 17 17 17 18 18 18
Other Noncurrent Operating Liabilities		 15 17 17 17 18 18 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 254 248 241 233 226 221 213
Total Preferred & Common Equity		 254 248 241 233 226 221 213
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 254 248 241 233 226 221 213
Common Stock		 387 397 400 404 412 416 420
Retained Earnings		 -133 -149 -159 -171 -185 -195 -206

Annual Metrics And Ratios for MaxCyte

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 30.59% -6.72% -6.45%
EBITDA Growth		 -62.34% -86.07% -3.53%
EBIT Growth		 -50.43% -76.53% -6.00%
NOPAT Growth		 -50.43% -76.53% -6.00%
Net Income Growth		 -23.52% -60.89% -8.26%
EPS Growth		 -9.52% -60.87% -5.41%
Operating Cash Flow Growth		 -38.42% -46.70% -27.32%
Free Cash Flow Firm Growth		 -120.44% 25.85% -9.82%
Invested Capital Growth		 239.07% -21.36% -23.65%
Revenue Q/Q Growth		 5.41% 8.52% -15.29%
EBITDA Q/Q Growth		 -11.28% -2.53% -7.27%
EBIT Q/Q Growth		 -7.02% -2.86% -10.36%
NOPAT Q/Q Growth		 -7.02% -2.86% -10.36%
Net Income Q/Q Growth		 0.27% -1.25% -14.88%
EPS Q/Q Growth		 -4.55% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -53.08% 24.58% -46.80%
Free Cash Flow Firm Q/Q Growth		 0.00% 21.94% -26.37%
Invested Capital Q/Q Growth		 23.58% -15.24% -4.11%
Profitability Metrics		 - - -
Gross Margin		 88.48% 88.51% 81.62%
EBITDA Margin		 -61.75% -123.17% -136.30%
Operating Margin		 -61.82% -116.98% -132.54%
EBIT Margin		 -61.82% -116.98% -132.54%
Profit (Net Income) Margin		 -53.25% -91.85% -106.29%
Tax Burden Percent		 100.00% 100.00% 100.00%
Interest Burden Percent		 86.15% 78.52% 80.19%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -111.09% -142.15% -194.09%
ROIC Less NNEP Spread (ROIC-NNEP)		 -109.26% -140.27% -191.49%
Return on Net Nonoperating Assets (RNNOA)		 101.97% 126.55% 175.36%
Return on Equity (ROE)		 -9.12% -15.60% -18.73%
Cash Return on Invested Capital (CROIC)		 -219.99% -118.24% -167.27%
Operating Return on Assets (OROA)		 -9.59% -17.41% -20.17%
Return on Assets (ROA)		 -8.26% -13.67% -16.17%
Return on Common Equity (ROCE)		 -9.12% -15.60% -18.73%
Return on Equity Simple (ROE_SIMPLE)		 -9.28% -16.33% -19.91%
Net Operating Profit after Tax (NOPAT)		 -19 -34 -36
NOPAT Margin		 -43.27% -81.89% -92.78%
Net Nonoperating Expense Percent (NNEP)		 -1.83% -1.88% -2.60%
Return On Investment Capital (ROIC_SIMPLE)		 - -14.56% -17.38%
Cost of Revenue to Revenue		 11.52% 11.49% 18.38%
SG&A Expenses to Revenue		 58.36% 72.83% 76.87%
R&D to Revenue		 44.09% 57.69% 57.54%
Operating Expenses to Revenue		 150.30% 205.50% 214.16%
Earnings before Interest and Taxes (EBIT)		 -27 -48 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -27 -51 -53
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 2.19 2.10 2.13
Price to Tangible Book Value (P/TBV)		 2.19 2.10 2.13
Price to Revenue (P/Rev)		 12.59 11.79 11.36
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 12.39 13.16 15.55
Enterprise Value to Revenue (EV/Rev)		 7.45 6.67 6.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -0.93 -0.90 -0.92
Leverage Ratio		 1.10 1.14 1.16
Compound Leverage Factor		 0.95 0.90 0.93
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 10.39 7.50 6.90
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 16.35 10.65 10.88
Quick Ratio		 15.58 9.75 10.09
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -38 -28 -31
Operating Cash Flow to CapEx		 -80.01% -587.54% -1,672.32%
Free Cash Flow to Firm to Interest Expense		 -298.64 0.00 0.00
Operating Cash Flow to Interest Expense		 -116.40 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -261.89 0.00 0.00
Efficiency Ratios		 - - -
Asset Turnover		 0.16 0.15 0.15
Accounts Receivable Turnover		 4.43 4.38 7.39
Inventory Turnover		 0.74 0.46 0.67
Fixed Asset Turnover		 2.82 1.75 1.79
Accounts Payable Turnover		 4.83 9.16 6.76
Days Sales Outstanding (DSO)		 82.32 83.39 49.42
Days Inventory Outstanding (DIO)		 493.50 800.89 543.46
Days Payable Outstanding (DPO)		 75.62 39.83 54.00
Cash Conversion Cycle (CCC)		 500.20 844.44 538.88
Capital & Investment Metrics		 - - -
Invested Capital		 27 21 16
Invested Capital Turnover		 2.57 1.74 2.09
Increase / (Decrease) in Invested Capital		 19 -5.69 -4.95
Enterprise Value (EV)		 330 276 249
Market Capitalization		 557 487 439
Book Value per Share		 $2.49 $2.24 $1.96
Tangible Book Value per Share		 $2.49 $2.24 $1.96
Total Capital		 254 232 206
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -227 -211 -190
Capital Expenditures (CapEx)		 18 3.69 1.65
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 9.50 4.05 1.43
Debt-free Net Working Capital (DFNWC)		 237 172 156
Net Working Capital (NWC)		 237 172 156
Net Nonoperating Expense (NNE)		 4.42 4.11 5.22
Net Nonoperating Obligations (NNO)		 -227 -211 -190
Total Depreciation and Amortization (D&A)		 0.03 -2.55 -1.45
Debt-free, Cash-free Net Working Capital to Revenue		 21.46% 9.81% 3.69%
Debt-free Net Working Capital to Revenue		 535.10% 417.41% 403.63%
Net Working Capital to Revenue		 535.10% 417.41% 403.63%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($0.23) ($0.37) ($0.39)
Adjusted Weighted Average Basic Shares Outstanding		 101.70M 103.27M 104.85M
Adjusted Diluted Earnings per Share		 ($0.23) ($0.37) ($0.39)
Adjusted Weighted Average Diluted Shares Outstanding		 101.70M 103.27M 104.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 102.90M 104.13M 106.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -19 -34 -36
Normalized NOPAT Margin		 -43.27% -81.89% -92.78%
Pre Tax Income Margin		 -53.25% -91.85% -106.29%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -215.44 0.00 0.00
NOPAT to Interest Expense		 -150.81 0.00 0.00
EBIT Less CapEx to Interest Expense		 -360.93 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -296.30 0.00 0.00
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MaxCyte

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 4.97% 22.37% -25.99% -5.88% -24.79% 26.10% 32.25% 15.33% 2.00% -44.51%
EBITDA Growth		 -273.94% -60.62% -276.42% -66.88% -81.20% -17.11% 5.73% 9.95% -0.15% -46.10%
EBIT Growth		 -215.69% -36.23% -216.85% -49.60% -80.91% -19.92% 6.85% 8.45% -0.72% -59.35%
NOPAT Growth		 -215.69% -36.23% -216.85% -49.60% -80.91% -19.92% 6.85% 8.45% -0.72% -59.35%
Net Income Growth		 -140.03% 1.33% -167.55% -27.26% -74.88% -9.73% 12.46% 10.82% -2.72% -100.78%
EPS Growth		 -100.00% -25.00% 0.00% -25.00% -83.33% 0.00% 0.00% 10.00% 0.00% 0.00%
Operating Cash Flow Growth		 -757.56% -533.83% -17.05% -1,200.04% -39.13% 116.12% -144.31% 52.16% 46.70% -897.25%
Free Cash Flow Firm Growth		 -88.35% 0.00% -11.38% -9.78% 30.93% 100.08% 50.32% 72.73% 86.06% -20,694.44%
Invested Capital Growth		 161.88% 239.07% 68.00% 56.84% 14.67% -21.36% 2.80% -13.76% -32.52% -23.65%
Revenue Q/Q Growth		 10.77% 16.73% -30.97% 5.45% -11.49% 95.71% -27.59% -8.05% -21.72% 6.47%
EBITDA Q/Q Growth		 5.30% 7.34% -90.01% -0.09% -2.83% 40.11% -46.24% 4.40% -14.36% 12.63%
EBIT Q/Q Growth		 11.75% 12.46% -95.20% 0.80% -6.72% 41.97% -51.63% 2.50% -17.42% 8.20%
NOPAT Q/Q Growth		 11.75% 12.46% -95.20% 0.80% -6.72% 41.97% -51.63% 2.50% -17.42% 8.20%
Net Income Q/Q Growth		 22.11% 25.24% -126.25% 3.40% -7.03% 53.09% -80.51% 1.59% -23.27% 8.31%
EPS Q/Q Growth		 25.00% 16.67% 0.00% 0.00% -10.00% 0.00% 0.00% 0.00% -22.22% 0.00%
Operating Cash Flow Q/Q Growth		 -744.57% -2.79% 28.96% -133.70% 18.48% 111.91% -1,176.09% 54.24% 9.16% -78.11%
Free Cash Flow Firm Q/Q Growth		 -13.11% -25.55% 20.85% 2.34% 28.84% 100.15% -45,646.57% 46.40% 63.61% -126.20%
Invested Capital Q/Q Growth		 35.86% 23.58% -13.00% 7.37% -0.67% -15.24% 13.72% -9.93% -22.27% -4.11%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 87.14% 87.55% 88.34% 84.78% 90.09% 89.96% 87.63% 85.73% 76.38% 73.76%
EBITDA Margin		 -74.43% -59.08% -162.62% -154.35% -179.32% -54.87% -115.91% -120.52% -176.07% -144.49%
Operating Margin		 -72.46% -54.34% -153.66% -144.56% -174.31% -51.68% -108.23% -114.76% -172.13% -148.42%
EBIT Margin		 -72.46% -54.34% -153.66% -144.56% -174.31% -51.68% -108.23% -114.76% -172.13% -148.42%
Profit (Net Income) Margin		 -60.45% -38.72% -126.89% -116.24% -140.57% -33.69% -83.99% -89.89% -141.56% -121.92%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 83.42% 71.25% 82.58% 80.41% 80.64% 65.19% 77.60% 78.33% 82.24% 82.14%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -143.07% -97.66% -240.12% -202.15% -200.73% -62.80% -142.08% -157.59% -265.56% -217.35%
ROIC Less NNEP Spread (ROIC-NNEP)		 -142.65% -97.62% -239.42% -201.55% -200.06% -62.98% -141.64% -157.11% -264.71% -216.57%
Return on Net Nonoperating Assets (RNNOA)		 134.46% 91.11% 222.07% 185.08% 181.09% 56.82% 127.61% 141.37% 240.19% 198.33%
Return on Equity (ROE)		 -8.61% -6.55% -18.05% -17.07% -19.64% -5.99% -14.47% -16.22% -25.37% -19.02%
Cash Return on Invested Capital (CROIC)		 0.00% -219.99% -188.56% -184.19% -155.79% -118.24% -144.00% -125.12% -118.12% -167.27%
Operating Return on Assets (OROA)		 -10.79% -8.43% -22.14% -20.97% -23.98% -7.69% -17.68% -19.95% -30.46% -22.58%
Return on Assets (ROA)		 -9.00% -6.00% -18.29% -16.86% -19.34% -5.01% -13.72% -15.63% -25.05% -18.55%
Return on Common Equity (ROCE)		 -8.61% -6.55% -18.05% -17.07% -19.64% -5.99% -14.47% -16.22% -25.37% -19.02%
Return on Equity Simple (ROE_SIMPLE)		 -9.29% 0.00% -12.26% -13.54% -16.05% 0.00% -16.15% -16.01% -16.75% 0.00%
Net Operating Profit after Tax (NOPAT)		 -5.40 -4.73 -9.22 -9.15 -9.77 -5.67 -8.59 -8.38 -9.84 -9.03
NOPAT Margin		 -50.72% -38.04% -107.56% -101.20% -122.02% -36.18% -75.76% -80.33% -120.49% -103.90%
Net Nonoperating Expense Percent (NNEP)		 -0.42% -0.03% -0.70% -0.60% -0.67% 0.18% -0.44% -0.48% -0.85% -0.78%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -2.44% - - - -4.38%
Cost of Revenue to Revenue		 12.86% 12.45% 11.66% 15.22% 9.91% 10.04% 12.37% 14.27% 23.62% 26.24%
SG&A Expenses to Revenue		 60.55% 45.48% 87.44% 84.74% 85.21% 51.62% 62.63% 73.25% 94.87% 82.90%
R&D to Revenue		 50.03% 46.10% 70.51% 62.63% 78.26% 37.29% 58.88% 53.88% 65.12% 53.08%
Operating Expenses to Revenue		 159.60% 141.90% 242.00% 229.35% 264.41% 141.64% 195.86% 200.49% 248.52% 222.18%
Earnings before Interest and Taxes (EBIT)		 -7.71 -6.75 -13 -13 -14 -8.10 -12 -12 -14 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -7.92 -7.34 -14 -14 -14 -8.60 -13 -13 -14 -13
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.60 2.19 2.06 1.96 1.38 2.10 1.93 1.85 1.92 2.13
Price to Tangible Book Value (P/TBV)		 2.60 2.19 2.06 1.96 1.38 2.10 1.93 1.85 1.92 2.13
Price to Revenue (P/Rev)		 15.75 12.59 12.35 11.63 8.49 11.79 9.90 9.02 8.96 11.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.88 12.39 12.29 10.33 4.62 13.16 9.82 9.79 12.73 15.55
Enterprise Value to Revenue (EV/Rev)		 10.20 7.45 6.90 6.31 3.00 6.67 5.31 4.62 4.65 6.43
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.94 -0.93 -0.93 -0.92 -0.91 -0.90 -0.90 -0.90 -0.91 -0.92
Leverage Ratio		 1.09 1.10 1.12 1.13 1.13 1.14 1.14 1.13 1.15 1.16
Compound Leverage Factor		 0.91 0.79 0.93 0.91 0.91 0.74 0.88 0.89 0.95 0.95
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 12.80 10.62 9.29 9.55 5.77 8.00 8.07 7.85 6.53 7.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 15.05 16.35 14.81 17.92 12.87 10.65 13.26 14.31 9.81 10.88
Quick Ratio		 14.38 15.58 14.06 16.94 11.92 9.75 12.13 13.19 8.99 10.09
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -19 -24 -19 -18 -13 0.02 -9.24 -4.95 -1.80 -4.08
Operating Cash Flow to CapEx		 -170.25% -277.36% -279.15% -1,993.10% -1,144.17% 107.21% -1,313.93% -1,644.22% -1,081.53% -5,320.41%
Free Cash Flow to Firm to Interest Expense		 -161.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -51.04 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -81.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.15 0.16 0.14 0.15 0.14 0.15 0.16 0.17 0.18 0.15
Accounts Receivable Turnover		 5.93 4.43 4.60 5.41 4.65 4.38 5.77 7.46 7.17 7.39
Inventory Turnover		 0.79 0.74 0.60 0.56 0.46 0.46 0.46 0.47 0.56 0.67
Fixed Asset Turnover		 2.82 2.82 2.16 1.81 1.63 1.75 1.85 1.97 2.04 1.79
Accounts Payable Turnover		 3.40 4.83 1.28 2.61 3.72 9.16 1.99 4.11 5.53 6.76
Days Sales Outstanding (DSO)		 61.57 82.32 79.28 67.47 78.55 83.39 63.31 48.95 50.93 49.42
Days Inventory Outstanding (DIO)		 460.65 493.50 610.57 646.47 791.31 800.89 788.35 769.97 654.56 543.46
Days Payable Outstanding (DPO)		 107.34 75.62 285.16 140.01 98.06 39.83 183.60 88.73 66.00 54.00
Cash Conversion Cycle (CCC)		 414.89 500.20 404.70 573.93 771.80 844.44 668.05 730.20 639.50 538.88
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 22 27 23 25 25 21 24 21 17 16
Invested Capital Turnover		 2.82 2.57 2.23 2.00 1.65 1.74 1.88 1.96 2.20 2.09
Increase / (Decrease) in Invested Capital		 13 19 9.38 9.01 3.16 -5.69 0.65 -3.42 -8.03 -4.95
Enterprise Value (EV)		 428 330 285 257 114 276 234 210 212 249
Market Capitalization		 661 557 509 473 323 487 436 410 409 439
Book Value per Share		 $2.50 $2.49 $2.41 $2.34 $2.25 $2.24 $2.17 $2.12 $2.03 $1.96
Tangible Book Value per Share		 $2.50 $2.49 $2.41 $2.34 $2.25 $2.24 $2.17 $2.12 $2.03 $1.96
Total Capital		 254 254 248 241 233 232 226 221 213 206
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -233 -227 -225 -216 -209 -211 -203 -200 -197 -190
Capital Expenditures (CapEx)		 3.48 2.19 1.55 0.51 0.72 0.92 0.80 0.29 0.41 0.15
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.63 9.50 5.15 7.31 7.45 4.05 7.68 6.04 1.46 1.43
Debt-free Net Working Capital (DFNWC)		 236 237 230 223 198 172 165 163 155 156
Net Working Capital (NWC)		 236 237 230 223 198 172 165 163 155 156
Net Nonoperating Expense (NNE)		 1.04 0.08 1.66 1.36 1.48 -0.39 0.93 1.00 1.72 1.57
Net Nonoperating Obligations (NNO)		 -233 -227 -225 -216 -209 -211 -203 -200 -197 -190
Total Depreciation and Amortization (D&A)		 -0.21 -0.59 -0.77 -0.89 -0.40 -0.50 -0.87 -0.60 -0.32 0.34
Debt-free, Cash-free Net Working Capital to Revenue		 6.27% 21.46% 12.48% 17.96% 19.58% 9.81% 17.44% 13.30% 3.19% 3.69%
Debt-free Net Working Capital to Revenue		 560.89% 535.10% 557.10% 549.13% 519.61% 417.41% 374.99% 359.53% 340.54% 403.63%
Net Working Capital to Revenue		 560.89% 535.10% 557.10% 549.13% 519.61% 417.41% 374.99% 359.53% 340.54% 403.63%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.06) ($0.05) ($0.11) ($0.10) ($0.11) ($0.05) ($0.09) ($0.09) ($0.11) ($0.10)
Adjusted Weighted Average Basic Shares Outstanding		 101.81M 101.70M 102.85M 103.06M 103.45M 103.27M 104.09M 104.64M 105.11M 104.85M
Adjusted Diluted Earnings per Share		 ($0.06) ($0.05) ($0.11) ($0.10) ($0.11) $0.00 $0.00 ($0.09) ($0.11) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 101.81M 101.70M 102.85M 103.06M 103.45M 103.27M 104.54M 104.64M 105.11M 104.85M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 102.05M 102.90M 103.05M 103.50M 103.58M 104.13M 104.54M 105.09M 105.48M 106.03M
Normalized Net Operating Profit after Tax (NOPAT)		 -5.40 -4.73 -9.22 -9.15 -9.77 -5.67 -8.59 -8.38 -9.84 -9.03
Normalized NOPAT Margin		 -50.72% -38.04% -107.56% -101.20% -122.02% -36.18% -75.76% -80.33% -120.49% -103.90%
Pre Tax Income Margin		 -60.45% -38.72% -126.89% -116.24% -140.57% -33.69% -83.99% -89.89% -141.56% -121.92%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -66.48 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 -46.54 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 -96.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -76.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

MaxCyte (NASDAQ:MXCT) has demonstrated a trend of operational challenges over the past four years with notable fluctuations in revenue and consistent net losses. Here's a detailed summary of the company's financial trends based on the last several reported quarters:

  • Operating revenue rose in Q4 2024 to $8.69 million from $8.16 million in Q3 2024, signaling a slight improvement in sales momentum.
  • Gross profit remained relatively stable, with Q4 2024 gross profit at $6.41 million, only a slight increase from $6.24 million in Q3 2024.
  • MaxCyte maintains a solid asset base, with total assets of approximately $248.6 million as of Q3 2024.
  • The company holds a substantial cash and short-term investment balance ($153 million combined at Q3 2024), supporting liquidity.
  • Operating expenses remain very high relative to revenue, contributing to ongoing operating losses.
  • Interest and investment income provide some offset to operating losses, with Q4 2024 other income of $2.3 million.
  • Cash flows from investing activities show active management of investments, with significant purchases and sales of investments each quarter.
  • MaxCyte has reported net losses each quarter since Q4 2022, with a Q4 2024 loss of approximately $10.6 million, consistent with prior quarters indicating ongoing profitability challenges.
  • Operating expenses, including marketing and research & development, have remained persistently high, peaking in some quarters above $22 million, greatly exceeding revenue.
  • Negative operating cash flow in recent quarters (e.g., -$7.8 million in Q4 2024) highlights cash burn issues due to continued net losses and large operating costs.

Summary: MaxCyte's financials show stable but modest revenue growth with consistent gross profit levels. However, the company's net losses and high operating expenses continue to pressure profitability and cash flow. While its cash reserves and investment portfolio offer a buffer, sustained losses raise concerns about the path to profitability. Investors should closely monitor MaxCyte's ability to control costs and translate its revenue growth into positive earnings.

10/24/25 10:38 AM ETAI Generated. May Contain Errors.

Frequently Asked Questions About MaxCyte's Financials

When does MaxCyte's fiscal year end?

According to the most recent income statement we have on file, MaxCyte's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has MaxCyte's net income changed over the last 2 years?

MaxCyte's net income appears to be on an upward trend, with a most recent value of -$41.06 million in 2024, rising from -$23.57 million in 2022. The previous period was -$37.92 million in 2023. See MaxCyte's forecast for analyst expectations on what’s next for the company.

What is MaxCyte's operating income?
MaxCyte's total operating income in 2024 was -$51.20 million, based on the following breakdown:
  • Total Gross Profit: $31.53 million
  • Total Operating Expenses: $82.72 million
How has MaxCyte's revenue changed over the last 2 years?

Over the last 2 years, MaxCyte's total revenue changed from $44.26 million in 2022 to $38.63 million in 2024, a change of -12.7%.

How much debt does MaxCyte have?

MaxCyte's total liabilities were at $33.22 million at the end of 2024, a 8.0% decrease from 2023, and a 1.6% increase since 2022.

How much cash does MaxCyte have?

In the past 2 years, MaxCyte's cash and equivalents has ranged from $11.07 million in 2022 to $46.51 million in 2023, and is currently $27.88 million as of their latest financial filing in 2024.

How has MaxCyte's book value per share changed over the last 2 years?

Over the last 2 years, MaxCyte's book value per share changed from 2.49 in 2022 to 1.96 in 2024, a change of -21.4%.


Related Companies

This page (NASDAQ:MXCT) was last updated on 10/24/2025 by MarketBeat.com Staff
From Our Partners
NEW LAW: Congress Approves Setup For Digital Dollar?
Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...
Goldco Precious Metals | Sponsoredtc pixel
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsoredtc pixel
Apple's secret partner
The Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...
The Oxford Club | Sponsoredtc pixel
Claim Your Share of $5.39 BILLION in AI Equity Checks
The U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...
Angel Publishing | Sponsoredtc pixel
Gold surges past $4,200 … but this has beat gold by 1,000x
Gold has surged past $4,200 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...
Weiss Ratings | Sponsoredtc pixel
If You Keep Cash In A U.S. Bank Account… Read This NOW
The Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...
Banyan Hill Publishing | Sponsoredtc pixel
Shots officially fired…
Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...
Brownstone Research | Sponsoredtc pixel
Trump cannot stop this train
Gallup reports that two-thirds of Americans now view socialism favorably — a shocking shift that one analyst s...
Porter & Company | Sponsoredtc pixel